Raffles Medical Group - Phillip Securities 2020-07-29: Near-Term Pain Extended By COVID-19

RAFFLES MEDICAL GROUP LTD (SGX:BSL) | SGinvestors.io RAFFLES MEDICAL GROUP LTD (SGX:BSL)

Raffles Medical Group - Near-Term Pain Extended By COVID-19

  • Raffles Medical (SGX:BSL)'s 1H20 revenue was below initial estimates by 9% due to impact from COVID-19 resulting in slower business momentum.
  • Decline in Hospital Services (-5.4% y-o-y) partially offset by better Healthcare Services (+6.8% y-o-y) due to the Group’s support of the government’s COVID-19 initiatives in Singapore.
  • Halt in hospital and clinic operations in China during 1H20 as a result of the COVID-19 outbreak expected to set the Group’s breakeven timeline back by up to a year.
  • We maintain our NEUTRAL recommendation on Raffles Medical with a lower target price of S$0.94 (previously S$0.99). We revise our FY20e earnings downwards by 25% taking into account pressure from slowing business momentum observed in 1H20.



The Positives


Healthcare Services saw revenue grow 6.8% y-o-y

  • Healthcare Services saw revenue grow 6.8% y-o-y from S$116.6mn to S$124.6mn in 1H20 as the Group rendered services to assist the government’s effort to tackle the COVID-19 pandemic, providing an alternative sources of income. These included providing air-border screening at Changi Airport, swabbing of foreign workers at the dormitories, as well as providing medical services to COVID-19 patients at the Changi Exhibition Centre- Community Care Facility.


The Negatives


Hospital Services fell 5.4% y-o-y from S$148.1mn to S$126.6mn on business disruptions across China and Singapore.

  • Initial outbreak of COVID-19 in China saw operations in China affected in 1Q20. This was followed by the 2-month Circuit Breaker in Singapore with non-essential activities (including services such as dental and health-screening) mandated to cease, hurting Raffles Medical’s business momentum in 1H20. As a result, Group revenue declined from S$255.3mn to S$241.4mn (-5.4% y-o-y) in 1H20.

Operating margin was lower (1H20: 10.0% vs. 1H19: 13.6%) due to higher staff costs (+4.8% y-o-y) and purchased and contracted services (+24.0%).

  • To support manpower demands from COVID-19-related projects with the government, the Group incurred higher outsourced recruitment agency costs as well as salaries from hiring of temporary staff. The increased costs were partially offset by government grants such as the Job Support Scheme (JSS), higher wage credit and property tax rebates. Nevertheless, operating profit fell 30.2% y-o-y to S$24.3mn (1H19: S$34.8mn).


Outlook


Gradual return to normalcy observed across operating geographies.

  • Raffles Medical has started to observe return of patient load in 3Q20 to pre-COVID-19 levels as both China and Singapore started to ease restrictions on businesses. As cross-border travel begins to ease, Hospital Services is likely to recover, as foreign patients make up 20 to 30% of revenue in Singapore. Margins will also revert to previous levels as contribution from in-patient services pick up.

Setback to operations in China

  • Raffles Hospital Chongqing (RHCQ) was slated to breakeven in FY21. However, the hospital saw less patient load in 1H20 with travel restrictions. As a result, the Group expects breakeven to be delayed by up to a year, prolonging gestations period and cost.
  • Raffles Hospital Shanghai is currently in the final stages of out-fitting and is expected to begin operations at end-FY20. However, this is barring further delays should the COVID-19 situation take a turn for the worse.


Maintain NEUTRAL with revised Target Price of S$0.94 (previous Target Price S$0.99).






Tay Wee Kuang Phillip Securities Research | https://www.stocksbnb.com/ 2020-07-29
SGX Stock Analyst Report NEUTRAL MAINTAIN NEUTRAL 0.94 DOWN 0.990



Advertisement



MOST TALKED ABOUT STOCKS / REITS OF THE WEEK



loading.......



ANALYSTS SAY


loading.......